Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in active psoriatic arthritis
NCT04314544Phase 3Completed
- Sponsor
- Sun Pharma
- Start
- Jul 2020
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of tildrakizumab in psoriatic arthritis (PsA) (2 arms), sponsored by Sun Pharma. Primary endpoint: American College of Rheumatology 20% Response at 24 weeks. Started Jul 2020; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04314544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314544.